PTC Therapeutics PTCT BR — Revenue
Other geography segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by PTC Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: PTC Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about PTC Therapeutics's br — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is PTC Therapeutics's BR — revenue?
- PTC Therapeutics (PTCT) reported BR — revenue of $41.21M in Q1 2026.
- How has PTC Therapeutics's BR — revenue changed year-over-year?
- PTC Therapeutics's BR — revenue increased by 333.6% year-over-year, from $9.51M to $41.21M.
- What is the long-term trend for PTC Therapeutics's BR — revenue?
- Over 2 years (2023 to 2025), PTC Therapeutics's BR — revenue has grown at a 5.8% compound annual growth rate (CAGR), from $58.61M to $65.66M.
- What does BR — revenue mean?
- This metric represents the total revenue generated from contracts with customers within the specific BR geographic or operational segment, excluding any assessed taxes such as sales or value-added taxes. It serves as a primary indicator of the commercial performance and market penetration of the company's therapeutic portfolio within this specific region. Tracking this figure allows investors to assess the revenue contribution and growth trajectory of the segment independent of broader corporate financial results.